Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

被引：0

作者：

Roch Houot

Guillaume Cartron

Fontanet Bijou

Sophie de Guibert

Gilles A. Salles

Christophe Fruchart

Krimo Bouabdallah

Marie Maerevoet

Pierre Feugier

Steven Le Gouill

Hervé Tilly

Rene-Olivier Casasnovas

Cécile Moluçon-Chabrot

Eric Van Den Neste

Pierre Zachee

Marc Andre

Christophe Bonnet

Corinne Haioun

Achiel Van Hoof

Koen Van Eygen

Lysiane Molina

Emmanuelle Nicolas-Virelizier

Philippe Ruminy

Franck Morschhauser

机构：

[1] University Hospital of Rennes,Department of Clinical Hematology

[2] Inserm 0203,Department of Clinical Hematology

[3] University of Rennes,Department of Hematology

[4] University Hospital of Montpellier,undefined

[5] UMR CNRS 5235,undefined

[6] University of Montpellier,undefined

[7] French Blood Institute,undefined

[8] Department of Hematology,undefined

[9] Centre Hospitalier Lyon-Sud,undefined

[10] Institut d’Hématologie de Basse Normandie (IHBN),undefined

[11] CHU,undefined

[12] Haematology,undefined

[13] CHU de Bordeaux,undefined

[14] Hematology,undefined

[15] Institut Jules Bordet,undefined

[16] CHU et INSERM 954,undefined

[17] Nancy Université,undefined

[18] Nantes University Hospital and UMR892 INSERM,undefined

[19] Centre Henri Becquerel,undefined

[20] Inserm U918,undefined

[21] Université de Rouen,undefined

[22] IRIB,undefined

[23] Hematology,undefined

[24] University Hospital,undefined

[25] Hematology Department,undefined

[26] CHU Clermont Ferrand,undefined

[27] Department of Hematology,undefined

[28] Cliniques Universitaires Saint-Luc,undefined

[29] AZ GROENINGE,undefined

[30] Hematology Department,undefined

[31] CHU UCL NAMUR,undefined

[32] Clinical Hematology,undefined

[33] CHU University of Liège,undefined

[34] Hôpital Henri Mondor,undefined

[35] Unité Hémopathies Lymphoide,undefined

[36] General Hospital St-Jan,undefined

[37] ZNA Stuivenberg,undefined

[38] Hematology,undefined

[39] CHU de Grenoble,undefined

[40] Hematology Department,undefined

[41] Centre Léon Bérard,undefined

[42] Université de Lille/ hopital Claude Huriez,undefined

来源：

Leukemia | 2019年 / 33卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：776 / 780

页数：4

共 50 条

[31] Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Christian, Beth A.
Huang, Ying
Ayyappan, Sabarish
Baiocchi, Robert A.
Brammer, Jonathan E.
Epperla, Narendranath
Jaglowski, Samantha
William, Basem M.
Awan, Farrukh T.
Maddocks, Kami J.
Blum, Kristie A.
BLOOD, 2019, 134
[32] Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
Diefenbach, Catherine
Kahl, Brad S.
McMillan, Andrew
Briones, Javier
Banerjee, Lalita
Cordoba, Raul
Miall, Fiona
Burke, John M.
Hirata, Jamie
Jiang, Yanwen
Paulson, Joseph N.
Chang, Yi Meng
Musick, Lisa
Abrisqueta, Pau
LANCET HAEMATOLOGY, 2021, 8 (12): : E891 - E901
[33] Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma
Kuruvilla, John
Taylor, Diane
Wang, Lisa
Blattler, Chantale
Keating, Armand
Crump, Michael
BLOOD, 2008, 112 (11) : 1049 - 1049
[34] A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).
Morrison, V. A.
Jung, S.
Johnson, J. L.
Leonard, J.
Cheson, B. D.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[35] Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study
Flowers, Christopher
Zinzani, Pier Luigi
Mayer, Jiri
Bijou, Fontanet
de Oliveira, Ana C.
Song, Yuqin
Zhang, Qingyuan
Merli, Michele
Bouabdallah, Krimo
Ganly, Peter S.
Zhang, Huilai
Yuen, Sam
Kingsley, Ed
Assouline, Sarit E.
Auer, Rebecca
Kim, Pil
Greenbaum, Adam
Huang, Sha
Delarue, Richard
Trotman, Judith
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
Leonard, John P.
Trneny, Marek
Izutsu, Koji
Fowler, Nathan H.
Hong, Xiaonan
Zhu, Jun
Zhang, Huilai
Offner, Fritz
Scheliga, Adriana
Nowakowski, Grzegorz S.
Pinto, Antonio
Re, Francesca
Fogliatto, Laura Maria
Scheinberg, Phillip
Flinn, Ian W.
Moreira, Claudia
Cabecadas, Jose
Liu, David
Kalambakas, Stacey
Fustier, Pierre
Wu, Chengqing
Gribben, John G.
Calaminici, Maria
Copie-Bergman, Christiane
Lopez-Guillermo, Armando
O'Connor, Owen
Williams, Michael
Suciu, Stefan
Levine, Benjamin
Kern, Julie
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1188 - +
[37] A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma
Fowler, Nathan
Pinto, Raisa M.
Cheah, Chan Yoon
Neelapu, Sattva S.
Turturro, Francesco
Hagemeister, Fredrick B.
Romaguera, Jorge E.
Fanale, Michelle A.
Fayad, Luis E.
Forbes, Sheryl
Khan, Janine
Feng, Lei
Samaniego, Felipe
Nastoupil, Loretta
BLOOD, 2015, 126 (23)
[38] A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma
Kim, Myung Sun
Banerjee, Titas
Chen, Andy
Danilov, Alexey
MacKinnon, Renee
Thurlow, Bria
Thakurta, Sujata
Orand, Kirsten
Degnin, Catherine
Park, Byung
Spurgeon, Stephen E.
LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 722 - 724
[39] Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
Nastoupil, Loretta J.
Westin, Jason R.
Hagemeister, Fredrick B.
Lee, Hun Ju
Fayad, Luis
Samaniego, Felipe
Ahmed, Sairah
Claret, Linda
Steiner, Raphael E.
Nair, Ranjit
Parmar, Simrit
Rodriguez, Maria Alma
Wang, Michael L.
Green, Michael R.
Davis, Eric
Neelapu, Sattva S.
Fowler, Nathan H.
BLOOD, 2019, 134
[40] Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory ( R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial.
Ghosh, Nilanjan
Salles, Gilles A.
Lossos, Izidore S.
Palomba, Maria Lia
Mehta, Amitkumar
Casasnovas, Olivier
Stevens, Don A.
Katakam, Sudhakar
Knapp, Andrea
Nielsen, Tina
Morschhauser, Franck
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →